The RNA contained Epithelial-cell adhesion-molecule (EpCAM) aptamers for targeted delivery and siRNA sequences for EpCAM gene silencing, and CD could load the first-line drug sorafenib for the targeted therapy of hepatocellular carcinoma through its hydrophobic cavity. The gene discussed is EPCAM; the disease is hepatocellular carcinoma.